Does anti-TNF alpha impact some patients’ cancer risk? Read the week’s top stories in gastroenterology
Click Here to Manage Email Alerts
Among the top stories in gastroenterology last week included findings showing anti-TNF alpha therapy is not linked to recurrent or new primary cancers in patients with inflammatory bowel disease and other immune-mediated diseases who previously had cancer.
A Mayo Clinic doctor’s insight on the unique obstacles that pregnancy presents in treating inflammatory bowel disease was another top story.
Anti-TNF alpha not linked with recurrent, new primary cancers in inflammatory bowel disease
Patients with inflammatory bowel disease and other immune-mediated diseases treated with anti-TNF alpha who previously had cancer are not at greater risk for recurrent or new primary cancers, according to the results of a population-based study. Read more.
Pregnancy presents additional challenges in inflammatory bowel disease
Pregnancy has the potential to present some difficult medical scenarios for women with inflammatory bowel disease, according to Sunanda V. Kane, MD, MSPH, FACG, of the Mayo Clinic in Rochester, Minnesota. Read more.
Switch to Entyvio after calcineurin inhibitor induction safe, effective for ulcerative colitis
Transitioning to Entyvio after achieving remission with calcineurin inhibitor induction therapy was safe and effective for patients with ulcerative colitis, according to study results. Read more.
Early colonoscopy does not improve lower GI bleeding outcomes
Moving patients to colonoscopy within 24 hours of hospital admission for acute lower gastrointestinal bleeding does not reduce further bleeding or mortality, according to the results of a meta-analysis published in Clinical Gastroenterology and Hepatology. Read more.
Breath test helps identify colorectal cancer
A non-invasive breath test that measures exhaled volatile organic compounds may help in the diagnosis of colorectal cancer and advanced adenomas, according to results of a multicenter study. Read more.